ImmuCell (NASDAQ:ICCC) will issue its quarterly earnings data after the market closes on Tuesday, November 13th.

ImmuCell (NASDAQ:ICCC) last issued its quarterly earnings results on Monday, August 13th. The biotechnology company reported ($0.05) EPS for the quarter. ImmuCell had a negative return on equity of 4.36% and a negative net margin of 14.07%. The company had revenue of $3.02 million during the quarter.

Shares of ICCC opened at $7.63 on Friday. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.25 and a quick ratio of 2.91. ImmuCell has a 52 week low of $6.50 and a 52 week high of $9.30.

ICCC has been the topic of a number of analyst reports. TheStreet raised ImmuCell from a “d+” rating to a “c” rating in a research report on Tuesday, September 18th. ValuEngine raised ImmuCell from a “hold” rating to a “buy” rating in a research report on Tuesday, August 28th.

COPYRIGHT VIOLATION NOTICE: This article was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at

About ImmuCell

ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company primarily offers First Defense, an orally delivered scours preventive product for newborn calves.

Read More: Diversification For Individual Investors

Earnings History for ImmuCell (NASDAQ:ICCC)

Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with's FREE daily email newsletter.